News Releases
NervGen Provides Quarterly “At-The-Market” Equity Program and Grant of Options Update
VANCOUVER, Canada July 7, 2025 – NervGen Pharma Corp. (“NervGen” or the “Company”) (TSX-V: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing innovative
NervGen Strengthens Board Leadership to Accelerate Clinical and Corporate Growth
Dr. Adam Rogers appointed chair as company advances toward key milestones following positive topline chronic cohort results of Phase 1b/2a CONNECT SCI Study VANCOUVER,
NervGen Announces Clinical Leadership Transition as NVG-291 Continues to Advance Toward Late-Stage Development and Regulatory Milestones
VANCOUVER, Canada, July 1, 2025 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neuroreparative therapeutics, today announced that
NervGen Announces Appointment of Randall Kaye, MD to Chief Medical Advisor Role
Vancouver, Canada, June 18, 2025 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neuroreparative therapeutics, today announced the
NervGen Pharma Reports Positive Topline Data from the Chronic Cohort of its Phase 1b/2a Clinical Trial Evaluating NVG-291 in Spinal Cord Injury
Study met its primary endpoint by achieving statistical significance on one of its two pre-specified co-primary endpoints, demonstrating increased electrical connectivity between the brain and
NervGen Pharma to Present Topline Data for NVG-291 Phase 1b/2a Chronic Cohort Study at the American Spinal Injury Association Annual Scientific Meeting
VANCOUVER, Canada, May 21, 2025 – NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF), a clinical-stage biotechnology company dedicated to developing neuroreparative therapeutics, today announced that
NervGen Pharma Grants Stock Options
Vancouver, Canada. May 16, 2025 – NervGen Pharma Corp. (TSX-V: NGEN; OTCQB: NGENF), a clinical-stage biotechnology company dedicated to developing neuroreparative therapeutics, today announced that
NervGen Pharma Reports Q1 2025 Financial Results and Provides Operational Updates
Completed last subject, last visit in the chronic cohort, data readout targeted for early June 2025 Vancouver, Canada May 15, 2025 – NervGen Pharma
NervGen Pharma Announces Results of Annual General Meeting of Shareholders
All resolutions submitted for approval were passed by shareholders Vancouver, Canada, May 7, 2025 — NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF), a clinical-stage
NervGen Pharma to Present at the 2025 Bloom Burton & Co. Healthcare Investor Conference
Vancouver, Canada, April 21, 2025 — NervGen Pharma Corp. (TSX-V: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today announced its
NervGen Provides Quarterly “At-The-Market” Equity Program Update
Vancouver, British Columbia, April 9, 2025 – NervGen Pharma Corp. (“NervGen” or the “Company”) (TSX-V: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing
NervGen Pharma Reports 2024 Year-End Financial Results and Provides Business Updates
Completed enrollment in the chronic cohort and commenced enrollment in the subacute cohort of its Phase 1b/2a clinical trial for lead drug candidate, NVG-291, in
NervGen Initiates Expanded Access Policy
The U.S. Food and Drug Administration (FDA) informed the company that an expanded access protocol for NVG-291 may proceed This news release constitutes a
NervGen Pharma to Host Virtual Investor Event
Key opinion leaders and company management will discuss the current spinal cord injury treatment landscape and NervGen’s Phase 1b/2a clinical trial evaluating NVG-291 in individuals
NervGen Pharma Grants Stock Options
Vancouver, Canada. March 14, 2025 – NervGen Pharma Corp. (TSX-V: NGEN; OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today announced that